Incyte Corporation

This is the first study in humans to test the safety and side effects of an experimental drug called INCA036873. It will enroll 280 adults with advanced solid tumors or blood cancers that have worsened despite previous treatments. The main goal is to find the highest dose patient…

This study compares two different combinations of medications given after a stem cell transplant to prevent graft-versus-host disease (GVHD), where donor cells attack the patient's body. Researchers want to see which drug combination better helps patients survive without developi…

This study is testing an oral medication called povorcitinib in teenagers with moderate to severe hidradenitis suppurativa (HS), a painful skin condition. Over 54 weeks, researchers will measure how safe the drug is, how the body processes it, and whether it reduces HS symptoms l…

This study is testing an experimental drug called axatilimab for Chinese patients with chronic graft-versus-host disease (cGVHD) that has returned or hasn't improved with standard treatments. cGVHD is a serious complication that can occur after a stem cell transplant, where the d…

This study is testing whether adding a new drug called axatilimab to standard steroid treatment works better than steroids alone for people with moderate to severe chronic graft-versus-host disease (cGVHD). cGVHD is a serious complication where the donor's immune cells attack the…

This study allows patients with blood cancers who are benefiting from tafasitamab treatment in previous trials to continue receiving the medication. The main goal is to monitor safety while providing ongoing treatment to those who need it. Only patients already responding well to…

This study is testing whether a cream called ruxolitinib is safe and effective at helping skin regain its natural color in children aged 6 to 12 with nonsegmental vitiligo. About 250 children will apply the cream or a placebo to see if it reduces the white patches on their face a…

This study allows people with hidradenitis suppurativa (HS) who benefited from the drug povorcitinib in earlier trials to continue taking it. The main goal is to monitor long-term safety and side effects in about 600 participants. It's for people who did well on the medication an…

This study is testing whether a new drug called axatilimab works better than current standard treatments for children with chronic graft-versus-host disease (cGVHD) who haven't responded to at least two previous therapies. The trial will involve 60 children aged 2 to 18 years who…

This is an early-stage study to test the safety and find the right dose of a new drug called INCA033989. It will be given alone or combined with an existing drug (ruxolitinib) to 225 people with certain blood cancers called myeloproliferative neoplasms. The main goal is to see ho…

This is the first study in people to test a new drug called INCB161734, which is designed to target a specific genetic change (KRAS G12D mutation) found in some advanced solid tumors. The main goals are to find a safe dose and see how well the drug is tolerated, both by itself an…

This study is testing an experimental drug called INCB123667 for women with platinum-resistant ovarian cancer whose tumors have a specific marker called cyclin E1 overexpression. The trial aims to see if the drug is safe and can shrink tumors in 160 participants who have tried 1-…

This study is testing a cream called ruxolitinib to see if it safely reduces the severity and itch of moderate eczema in children and adolescents aged 6 to 18. It is for kids whose eczema hasn't responded well enough to standard topical treatments like steroid creams. The trial w…

This early-stage study is testing a new drug called INCB123667, both alone and in combination with other cancer treatments, for people with advanced solid tumors that have stopped responding to standard therapies. The main goals are to find safe doses, understand how the drug wor…

This is an early-stage study to test the safety and find the right dose of a new drug called INCA033989. It will be given alone or combined with an existing drug, ruxolitinib, to about 230 people with myeloproliferative neoplasms (MPNs), which are a group of blood cancers. The ma…

This is the first study in people to test a new drug called INCA036978 for myeloproliferative neoplasms, a group of rare blood cancers. The main goal is to find a safe dose and understand the drug's side effects in up to 218 participants with myelofibrosis, polycythemia vera, or …

This program provides early access to an immunotherapy drug called retifanlimab, given alongside standard chemotherapy drugs carboplatin and paclitaxel. It's for adults with advanced or spreading squamous cell carcinoma of the anal canal who cannot join other clinical trials or u…

This is the first study in humans of a new drug called INCA33890 for people with advanced or spreading solid tumors. Researchers will test different doses in 408 participants to find the safest amount and see how the body processes the drug. The main goals are to understand side …

This is the first study in people to test a new drug called INCB160058 for myeloproliferative neoplasms (MPNs), a group of rare blood cancers. The main goal is to find a safe dose and see how the body processes the drug in 186 adults whose current treatments have stopped working.…

This early-stage study is testing the safety of a cream called ruxolitinib for people with hidradenitis suppurativa, a chronic inflammatory skin disease. It will enroll 24 adults and adolescents to see what side effects occur when the cream is applied to a large area of the skin.…

This study is testing an experimental pill called povorcitinib for adults whose moderate to severe asthma is not well controlled by their current inhalers. Researchers want to see if different doses of the pill can improve lung function and reduce asthma attacks over 24 weeks. Th…

This is the first study in people to test a new drug called INCA035784 for rare blood cancers called myeloproliferative neoplasms. The main goal is to find a safe dose and see what side effects it causes in 120 adults who have not responded well to other treatments. Researchers w…

This study is testing whether a cream called ruxolitinib is safe and effective at helping restore skin color in children with nonsegmental vitiligo. It will involve about 180 children and is a late-stage (Phase 3) trial. The main goal is to see if the cream can improve the appear…

This study is testing whether an oral medication called povorcitinib can reduce severe itching and heal skin lesions in people with prurigo nodularis, a chronic skin condition. About 330 adults with moderate-to-severe symptoms who haven't responded well to other treatments will r…

This large, late-stage study is testing whether adding a new experimental drug called INCA33890 to standard chemotherapy can better control advanced colorectal cancer that has spread. It will involve 700 people with a specific type of cancer (microsatellite stable) who have not y…

This is an expanded access program that allows one patient with chronic graft-versus-host disease (GVHD) to receive the investigational drug axatilimab outside of a formal clinical trial. The program requires special approvals from the company, ethics committees, and regulatory a…

This study is testing whether a new drug called INCB123667 works better than standard chemotherapy for women with a specific type of advanced ovarian cancer that has stopped responding to platinum-based drugs. It will involve about 466 participants whose cancer has a specific bio…

This study is testing whether a cream called ruxolitinib can safely reduce painful lumps and sores for people with hidradenitis suppurativa (HS), a chronic inflammatory skin condition. About 550 participants with mild to moderate HS will apply either the active cream or a placebo…

This study is testing whether an investigational drug called INCB000928 can slow or stop the formation of new, abnormal bone in people with fibrodysplasia ossificans progressiva (FOP), a rare and severe genetic disorder. About 98 participants, including children as young as 2, wi…

This study is testing whether adding a new drug called axatilimab to an existing drug (ruxolitinib) works better for controlling chronic Graft-Versus-Host Disease (cGVHD). It will involve about 120 people aged 12 and older who have recently been diagnosed with moderate or severe …

This study is testing whether a cream containing the drug ruxolitinib can safely reduce painful skin lumps and abscesses in people with hidradenitis suppurativa (HS). About 400 participants with mild to moderate HS will apply either the active cream or a placebo cream to see whic…

This study is testing an investigational drug called tafasitamab in adults with primary autoimmune blood cell disorders, specifically immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA). The main goals are to see if the drug is safe and if it can help raise…

This study is testing whether an investigational drug called povorcitinib can reduce the severe, constant itching and heal the skin bumps caused by prurigo nodularis. It will involve about 330 adults with this condition who have not found relief from other treatments. Participant…

This study aims to collect information from 1,500 adults who recently received a stem cell transplant from a donor. Researchers want to better understand who develops chronic Graft-Versus-Host Disease (cGVHD), a serious complication where the donor cells attack the patient's body…

This study looks at pregnancy outcomes for women with eczema who used ruxolitinib cream during pregnancy compared to those who used standard steroid creams. Researchers will analyze health insurance claims data from over 5,600 women to check for birth defects and other pregnancy …

This early-stage study aims to understand how eating food and taking other common medications affect how the body processes a new drug called INCB123667. It involves 51 healthy adult volunteers who will take the drug under different conditions. The main goal is to gather safety d…

This study aims to understand if using ruxolitinib cream for mild to moderate eczema during pregnancy affects the baby's health. Researchers will compare pregnancy outcomes and infant health between women who used the cream and those who did not. The study is observational, meani…

This is a very early study to understand how a new drug called INCA033989 moves through the body and to check its safety. It will involve 72 healthy adults who will receive a single dose, either as an injection under the skin or through an IV. The main goals are to measure the dr…